Geron Corporation

NASDAQ:GERN

Biotechnology

Healthcare
$0.99 +4.07%

+$0.05 today

Market cap
$638.38M
Beta
0.60
P/E (TTM)
-12.3
EPS (TTM)
-$0.10
52W Low $1.04High $2.01

Volume 34.97M

Average 16.28M

GERN Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Geron CorporationNASDAQ: GERN

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Income Tax Expense vs competitors

How GERN compares with its peers on the latest reported figures

  • GERN's LTM Mar 2026 income tax expense of $0 is the 3rd highest of the 8 companies compared; the peer median is $0.
  • Income tax expense amounts to 0.0% of revenue for GERN, versus a peer median of 6.1%.
GERN Competitors Peer median
Income Tax Expense for GERN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$354.98M -9.3%+26.1%6.1%
DMRADamora Therapeutics, Inc.LTM Mar 2026$90K +109.3%——
GERNGeron CorporationLTM Mar 2026$0 ——0.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 ———
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$0 ——0.0%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$68K -103.8%——
COAGHemab Therapeutics Holdings, Inc. Common StockFY2025-$227K ———
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026-$242.26M -25708.8%—80.8%
Peer median (excluding GERN) $0-56.6%+26.1%6.1%

Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.39M596K237K76.99M183.88M
Cost of Revenue0001.26M4.75M
Gross Profit1.39M596K237K75.74M179.14M
Gross Margin100.0%100.0%100.0%98.4%97.4%
Research & Development85.73M95.52M125.05M103.74M73.72M
Selling, General & Admin29.67M43.63M69.14M145.73M159.26M
Operating Expenses115.39M139.15M194.18M249.47M232.97M
Depreciation & Amortization783K868K1.03M1.22M1.2M
EBITDA(111.59M)(134.15M)(174.78M)(154.85M)(51.92M)
EBITDA Margin-8010.7%-22508.6%-73747.7%-201.1%-28.2%
Operating Income(114M)(138.55M)(193.94M)(173.73M)(53.84M)
Operating Margin-8183.7%-23246.6%-81832.9%-225.6%-29.3%
Interest Income527K2.53M18.15M19.61M18.12M
Interest Expense3.74M6.88M8.31M18.5M32.66M
Other Income / Expenses(2.11M)(3.35M)9.82M(840K)(31.95M)
Income Before Tax(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Pre-Tax Margin-8335.4%-23808.9%-77690.7%-226.7%-46.7%
Income Tax Expense00000
Net Income(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Net Margin-8335.4%-23808.9%-77690.7%-226.7%-46.7%
EPS (Basic)(0.37)(0.37)(0.32)(0.27)(0.13)
EPS (Diluted)(0.37)(0.37)(0.32)(0.27)(0.13)
Weighted Avg Shares327.63M380.78M570.65M646.03M666.66M
Weighted Avg Shares (Diluted)327.63M380.78M570.65M646.03M666.66M

Geron Corporation

NASDAQ:GERN

Intrinsic Alpha fair value

Locked

Current Price

$0.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.